Ono Pharmaceutical Co., Ltd. (OPHLY)
5.16
+0.05
(+0.98%)
USD |
OTCM |
Nov 13, 16:00
Ono Pharmaceutical Enterprise Value : 6.362B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 6.362B |
| November 12, 2026 | 6.292B |
| November 11, 2026 | 6.136B |
| November 10, 2026 | 6.221B |
| November 09, 2026 | 6.306B |
| November 06, 2026 | 6.010B |
| November 05, 2026 | 6.292B |
| November 04, 2026 | 6.161B |
| November 03, 2026 | 5.840B |
| November 02, 2026 | 5.911B |
| October 30, 2026 | 5.727B |
| October 29, 2026 | 5.657B |
| October 28, 2026 | 6.390B |
| October 27, 2026 | 6.334B |
| October 26, 2026 | 6.475B |
| October 23, 2026 | 6.516B |
| October 22, 2026 | 6.560B |
| October 21, 2026 | 6.461B |
| October 20, 2026 | 6.503B |
| October 19, 2026 | 6.207B |
| October 16, 2026 | 6.108B |
| October 15, 2026 | 6.031B |
| October 14, 2026 | 5.643B |
| October 13, 2026 | 5.798B |
| October 12, 2026 | 5.742B |
| Date | Value |
|---|---|
| October 09, 2026 | 5.770B |
| October 08, 2026 | 5.727B |
| October 07, 2026 | 5.756B |
| October 06, 2026 | 5.784B |
| October 05, 2026 | 5.826B |
| October 02, 2026 | 5.853B |
| October 01, 2026 | 5.911B |
| September 30, 2026 | 6.052B |
| September 29, 2026 | 6.614B |
| September 28, 2026 | 6.882B |
| September 25, 2026 | 6.712B |
| September 24, 2026 | 6.642B |
| September 23, 2026 | 6.825B |
| September 22, 2026 | 7.008B |
| September 21, 2026 | 6.656B |
| September 18, 2026 | 6.557B |
| September 17, 2026 | 6.585B |
| September 16, 2026 | 6.318B |
| September 15, 2026 | 6.445B |
| September 14, 2026 | 6.461B |
| September 11, 2026 | 6.445B |
| September 10, 2026 | 6.388B |
| September 09, 2026 | 6.487B |
| September 08, 2026 | 6.684B |
| September 04, 2026 | 6.684B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 94.93B |
| Daiichi Sankyo Co., Ltd. | 31.74B |
| Eisai Co., Ltd. | 8.931B |
| Chugai Pharmaceutical Co., Ltd. | 68.64B |
| Santen Pharmaceutical Co., Ltd. | 3.756B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 131.04M |
| Revenue (Quarterly) | 730.57M |
| Total Expenses (Quarterly) | 600.09M |
| EPS Diluted (Quarterly) | 0.0923 |
| Gross Profit Margin (Quarterly) | 75.29% |
| Profit Margin (Quarterly) | 17.94% |
| Earnings Yield | 6.52% |